Syncona Portfolio Companies Boost Interim Result; Launches New Company
Syncona Portfolio Companies Boost Interim Result; Launches New Company
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreSyncona Portfolio Companies Boost Interim Result; Launches New Company
Read more(Sharecast News) - Healthcare company Syncona reported a "robust" performance for the six months up to 30 September in which its net assets reached a value of £1,366.7m at 203,4p per share and a net asset value total return of 9.6% in the period.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreUK EXECUTIVE CHANGE SUMMARY: Kakuzi Acts To Prevent Human Rights Abuse
Read moreSyncona Investee Freeline Posts Widened Interim Loss On Higher Costs
Read more(Sharecast News) - Healthcare investment firm Syncona said on Friday that portfolio business Freeline Therapeutics had seen interim losses widen as a result of increased research and development costs.
Read moreUK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation
Read moreSyncona Life Science Portfolio Boosted By Autolus And Freeline
Read moreSyncona Investee Freeline Therapeutics Prices IPO In New York
Read more(Sharecast News) - Healthcare investment company Syncona announced on Friday that its portfolio company Freeline Therapeutics has priced its initial public offering in the United States.
Read moreUK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake
Read moreSyncona Investee Freeline Therapeutics Files For Possible US Listing
Read more(Sharecast News) - Healthcare investor Syncona said its portfolio company Freeline Therapeutics has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering (IPO).
Read moreSyncona's Investee Freeline Publishes Further Data For FLT180a
Read moreSyncona Investee Freeline Raises USD120 Million And Mulls US Listing
Read more